ex vivo-expanded autologous T cells IMA101
A preparation of autologous cytotoxic T lymphocytes, specifically recognizing certain tumor-associated antigens (TAAs), with potential antineoplastic activity. The endogenous T cells are isolated, expanded ex vivo, and reintroduced back into the patient. Upon administration, the ex vivo-expanded autologous T cells IMA101 target and kill tumor cells. The T cells are analyzed beforehand for their ability to specifically recognize certain TAAs, based on a proprietary antigen warehouse.
Synonym: | IMA101 T cells |
---|---|
US brand name: | ACTolog IMA101 |
Code name: | IMA101 |